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Abstract
The  discovery  of  RNA  interference  (RNAi)  as  a  naturally  occuring  phenomenon  in 
eukaryotic cells has risen an entire new field of possibilities in cancer research and therapy. 
siRNAs, small RNA structures (19-23bp), are gene-silencing substances which downregulate 
the  expression  of  specific  gene  sequences  by  using  this cell-innate  RNAi pathway.  The 
siRNA-mediated knockdown of apoptosis- and cancer-relevant genes in carcinoma cell lines 
appeared to be a promising application in the area of RNA-interference-based therapeutical 
studies. 
As continuative attempt to a single siRNA knockdown of the same gene, the aim of this 
study  was  to  find  possible  synergistic  functional  effects  in  the  extend  of  gene  – 
downregulation by combining synthetical siRNAs targeted at different cancer biomarkers in 
order to reduce proliferation and increase apoptosis of the target cell lines. For this multi – 
target approach, siRNAs were transfected as single agents and in various combinations of 
two to three sequences into carcinoma cell lines (607B, HT-29, MCF-7). Gene targets were 
chosen due to their role in preferably different apoptosis- and cancer relevant pathways for a 
wide range of potential effects. 
Using proliferation assays the most promising siRNAs, in combination, appeared to be 
galectin-1, sphingosin kinase 1, BCL-2, Her2/Neu, ß-catenin and EpCAM. For further 
validation, apoptosis assays and realtime PCR was performed. In order to find targets with 
selectivity on cancer cells, HUVECs (human umbilical vein endothelial cells) were used as 
control for somatic endothelial tissue. 
Successful downregulation of mRNAs were verified by qPCR-based quantification for all 
but two of the targets. siRNAs did not lose their potency when applied in combinations. 
Effects on proliferation rates and apoptosis induction were found to be dependent on the cell 
line. No synergistic effect was identified for all of the cancer cells used for any siRNA 
combination. 
Zusammenfassung
Die  Entdeckung  des  RNA  interference  Mechanismus  als  natürliches  Phänomen  in 
eukaryotischen Zellen führte zu einer Reihe neuer Möglichkeiten in Krebsforschung und – 
therapie. Dabei spielen siRNAs, kurze RNA Sequenzen (19-23bp), eine große Rolle indem 
sie die Expression spezifischer Gensequenzen herunterregulieren und im Rahmen des RNAi 
– Mechanismus als sogenannte „gene – silencing“ Substanzen wirken. Auf dem Gebiet von 
RNA-interference-basierenden  Studien  ist  dieser  siRNA  –  vermittelte  knockdown  von 
spezifischen apoptose- und krebsrelevanten Genen eine viel versprechende Anwendung.
Weiterführend zum knockdown eines Gens mittels spezifischer siRNA – Sequenz wurden in 
dieser  Arbeit  mehrere synthetisch hergestellte  siRNAs, deren Zielsequenzen verschiedene 
Karzinom  –  Biomarker  sind,  gemeinsam  in  Krebszelllinien  transfiziert,  um  mögliche 
Synergieeffekte  im Ausmass der  Downregulierung hervorzurufen.  Die dabei verwendeten 
siRNA – Zielsequenzen waren Gene aus verschiedensten metabolischen Pathways, um eine 
möglichst weitreichende Abdeckung zu erzielen.
Mittels  Proliferationstests  wurden  sechs  mögliche  siRNA –  Ziele  ermittelt:  galectin-1, 
sphingosin kinase 1, BCL-2, Her2/Neu, ß-catenin und EpCAM. Für eine weitere Validierung 
dieser  Ergebnisse  wurden  zusätzlich  Apoptosetests  und  realtime  PCRs durchgeführt.  Als 
Selektivitätskontrolle  für  somatisches  Endothelgewebe wurden HUVEC – Zellen  (human 
umbilical vein endothelial cells) verwendet.
Mit  Ausnahme  von  zwei  Gentargets  wurde  die  Herunterregulierung  von  mRNA mittels 
qPCR verifiziert.  Die siRNAs zeigten auch in  Kombination keinen Wirkungsverlust.  Die 
Induktion  von  Apoptose  und  die  Proliferationsraten  waren  stark  abhängig  von  der 
verwendeten Zelllinie, Synergieeffekte der siRNA-Kombinationen konnten jedoch in keiner 
der Krebszelllinien nachgewiesen werden.
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 1 Introduction
 1.1 RNA interference mechanism
RNA interference  (RNAi)  has  been  recognized  lately  as  an  important  mechanism  for 
controlling gene expression at a post-transcriptional level (1).
It was first discovered in Caenorhabditis elegans (2) but also operates in plants, fungi, flies 
and mammals and, in all likelihood, is an old mechanism in cells to eliminate undesired and 
foreign genes. Usually long stretches of dsRNA with perfect base-pairing, occuring in the 
cytoplasm are recognized and cleaved by the ribonuclease Dicer into duplexes with 19 paired 
nucleotides bearing 2-nt overhangs at both 3’-ends (3, 4, 5), called small interfering RNAs 
(siRNAs).
After  Dicer  cleavage,  these natural  siRNAs bind to the RNA-induced silencing complex 
(RISC) which contains Argonaut proteins that form a catalytic core (6). 
Argonaut proteins contain two domains, PAZ and PIWI. The PIWI domain is needed for the 
interaction with Dicer and has a nuclease activity that cleaves off target mRNAs (7) and 
therefore  essential  for  Argonaut  proteins  to  perform their  function.  RISC unwounds  the 
siRNA and the  sense  strand is  removed  for  degradation  by  cellular  nucleases  while  the 
antisense-strand leads the RISC complex to the target mRNA sequence where it is degraded 
by RISC endonuclease activity (8). 
The two categories of small RNAs produced by Dicer cleavage are small interfering RNAs 
(siRNAs) and microRNAs (miRNAs) which differ in origin and function but both siRNAs 
and miRNAs are 21- to 23-bp duplexes bearing 2-nt overhangs at the 3′ ends. In contrast to∼  
siRNAs,  miRNAs are derived from cleavage of  long,  single-stranded primary transcripts 
containing imperfectly matched hairpin-loop structures (9).
This naturally occuring process of RNAi  can be induced by the introduction of synthetic 
21- to 23-nt siRNA duplexes into cells. They bypass the requirement for processing of a∼  
long dsRNA mediated by Dicer (3) and cause post-transcriptional gene silencing by
 mimicking the Dicer cleavage product with their 3` dinucleotide overhangs.
Figure  1. Mechanism of  RNAi  .  The  inward transfer  of  
siRNA into the cell,  as  realized  in  this  project,  causes  a  
sequence-specific gene knock-down by avoiding the Dicer  
and directly binding the RISC complex instead. (taken from  
http://www.gene-
quantification.de/laborwelt_sirna_06_2006.pdf, legend and 
table adapted)
 1.2 Mechanisms of gene silencing
In plants  and animals,  primary microRNAs (pri-miRNAs),  are  processed  by Drosha and 
DGCR8 into precursor miRNAs and transported to the cytoplasm by exportin 5 (XPO5) 
where they are bound by a Dicer-containing pre-RISC which forms a guide sequence. This 
sequence binds to the corresponding target sequence in the 3` UTRs of cellular mRNAs. The 
catalytic core of RISC is AGO2. When the sequences are fully complementary, the catalytic 
domain of AGO2 triggers site-specific cleavage and degradation of the mRNA. When the 
base-pairing is incomplete, translational inhibition occurs. 
ShRNAs, just like miRNAs, are transported to the cytoplasm by XPO5, where the dsRNA is 
processed  into  21-25-nucleotide  fragments  by  Dicer  and  loaded  into  the  RISC.  These 
siRNAs are able to target different complementary sequences of cellular mRNAs and trigger 
their degradation by AGO2-mediated cleavage.
SiRNAs in the nucleus can trigger histone modification and chromatin remodelling which
Figure 2. Mechanisms of cellular gene silencing (10)
 also result in transcriptional gene silencing (10).
 1.3 Delivery of siRNAs
SiRNAs are hydrophilic and too big to cross the cell membrane unassisted. Therfore these 
molecules require appropriate delivery methods. Two main strategies of inward transfer to 
the target cells are common: viral and non-viral delivery. Whereas the viral delivery triggers 
the  RNAi  mechanism  through  promotor-expressed  siRNA  sequences  processed  from 
shRNAs  or  miRNA mimics,  chemically  synthesized  siRNAs  are  delivered  in  non-viral 
modes (10).
As things are now, stable and efficient siRNAs can be synthesized and delivered into cell 
lines but to work as potent drugs, siRNAs have to reach the tissues where the disease is 
caused. Furthermore the transport into the cytoplasm has to be ensured, otherwise siRNAs 
would be degraded in the endosome. Scientists are currently working on an overall delivery-
platform to find proper delivery systems for different indications (11).
The most common transfection reagents are cationic lipids, such as Lipofectamine 2000, 
likely the most widely used siRNA transfection enhancer.
The basic structure of cationic lipids consists of a positively charged head group and one or 
two hydrocarbon chains. The charged head group governs the interaction between the lipid 
and the  phosphate  backbone of  the nucleic  acid,  and facilitates  DNA condensation.  The 
positive surface charge of the liposomes also mediates the interaction of the nucleic acid and 
the cell membrane, allowing for fusion of the liposome/nucleic acid (“transfection complex“) 
with the negatively charged cell membrane. The transfection complex is believed to enter the 
cell  through  endocytosis.  Once inside  the  cell,  the  complex  must  escape  the  endosomal 
Figure 3. Delivery strategies for therapeutic siRNAs. Lipofectamin 2000 reagent, as a cationic lipid, belongs  
to c,  SNALPs encapsulate modified siRNAs into cationic or neutral  lipid bilayers  coated with diffusible  
PEG–lipid conjugates.  SNALPs allow siRNAs to be taken up by cells and released by endosomes. (10),  
legend adapted
pathway, diffuse through the cytoplasm, and enter the nucleus for gene expression (adapted 
from  http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-
Culture/Transfection/transfection-methods/Lipid-Transfection.html).
 
Figure 4. Lipofectamine™ 2 000 Transfection Reagent: Blue cells are those that express β-lactamase  
and therefore have been successfully transfected with the reporter vector. Green cells are untransfected.  
(figure  taken  from  http://www.invitrogen.com/site/us/en/home/Products-and-
Services/Applications/Protein-Expression-and-Analysis/Transfection-Selection/lipofectamine-2000.html,  
table adapted)
 1.4 RNAi – based therapeutics
Today most of the therapeutic approaches based on RNAi machinery use direct introduction 
of synthetic siRNAs into the target cell, as described above. These chemically synthesized 
small molecules can be modified to increase stability, promote efficiacy, block binding to 
unintended  targets  that  contain  mismatches  (specific  off-target  effects)  and  reduce 
immunostimulatory  effects  (general  off-target  effects).  Compared  to  promotor  expressed 
small  RNAs occurring in cells  like shRNAs or miRNAs, the effects  of siRNA-mediated 
knockdown  are  relatively  transient  and  the  levels  of  target  knockdown  are  sequence- 
dependent  (10).  Therefore  large  siRNA  screens  are  useful  to  discriminate  between 
efficiencies  of  different  siRNAs.  Using RNA interference  to  treat  human  diseases  is  an 
expandable field of future therapeutical aims. In human clinical trials, the first tested siRNA 
protocol  was the vascular  endothelial  growth factor  (VEGF)-targeted siRNA Bevasiranib 
(Acuity  Pharmaceuticals,  Philadelphia,  Pennylvania)  for  treatment  of  wet  age-related 
macular degeneration (10). The downregulation of VEGF after direct ocular injection of the 
siRNA showed a reduction of neovascularization in mice (12).
Table 1. Current clinical trials of RNAi-based therapeutics (10)
 1.5  siRNA Screens
In recent years, siRNA screens have become increasingly popular for determining the 
involvement of specific genes in cellular process. For a successful screen, the most important 
element is to find a specific assay which is usually the most time-consuming aspect in such 
approaches. 
The  ease  of  the  assay  is  often  inversely  proportional  to  its  specificity.  Cell  lethality  is 
probably the easiest phenotype to score, but it does not give much information about a gene’s 
function. An assay, in contrast, in which the function of synapses is directly measured using 
electrophysiological  techniques  is  specific,  but  expensive  and  probably  not  viable  on  a 
genome-wide scale. Therefore large-scale RNAi screens often have to find a compromise 
between specificity and practicality (31, 32)
In this  approach, I  used a  cell  proliferation-  and a caspase-assay to  determine effects  of 
specific  siRNAs  on  cell  proliferation  and  -apoptosis.  These  assays,  followed  by  mRNA 
quantification  with  qPCR,  seemed  to  give  adequate  information  in  the  extend  of  gene-
specific downregulation.
Genome-wide or focused siRNA screens can be used for identifying genes involved in 
assayed molecular effects, for example cell proliferation, migration, tumorigenesis and drug 
action or resistance. However, there are some inherent drawbacks of this methodology. 
Because of the lack of verification of successful target downregulation and off-target effects, 
a certain rate of false positive and false negative results is inevitable. Estimated rates of false 
negative are in the range of 8 % to up to 50 % for some screens (33). By pooling several 
siRNA sequences, the rate of false negative results can be minimized, but off-target effects 
caused by imperfect hybridization to mRNAs other than the targeted one increase. Keeping 
the high costs and great efforts need for genome-wide screens in mind, careful experimental 
design has be done prior to performing such screens. 
 
 
 1.6 Off-target effects
Human cells show huge complexicity in signaling cascades and protein interactions which is 
a major problem in the development of RNAi-based therapeutics. Drug delivery into the cell 
can cause unspecific effects, so called off-target effects, on the whole genome, transcriptome, 
metabolome or proteome. Off-target effects can be caused in a sequence-dependent manner 
by hybridization to mRNAs other than the targeted one despite a few mismatches, or in a 
sequence-independent manner by interaction with effector molecules such as proteins and 
receptors. An example of the latter is activation of the immune systeme by binding to Toll-
like receptors localized in the endosome.
 One of the gene targets in this study was Bcl-2, an anti-apoptotic protein, which inhibits the 
release  of  Cytochrome C in  mitochondria  and leads  to  apoptisis.  Proteins  of  the  B-cell 
lymphoma 2 (Bcl-2) family, which regulate the intrinsic apoptotic machinery, build a huge 
network in cells. Such protein-networks often have responding mechanisms to compensate a 
knockdown of a single gene. Due to this complex network, targeting only one gene in order 
to increase apoptosis seemed to be inefficient in this approach. Even at the risk of getting off-
target effects, several siRNAs were pooled in order to achieve gene-specific results. 
Based on this facts, I performed a multi-target approach in order to find the most potent 
inhibitory combinations of siRNAs in cancer cells. Preferably using multiple siRNA targets 
from different intrinsic pathways, aim of the project was to find potential synergistic effects 
that increase sequence-specific knockdown and therefore causing increased apoptosis in the 
transfected carcinoma cell lines. As to the fact that siRNA have shown to be effective in 
already very low nanomolar concentrations in various in-vitro models (8), the concentrations 
as used in this approach were 1 nM, 10 nM and 100 nM. 
The  cell  lines  chosen  for  transfection  were  607B,  a human  melanoma  cell  line  which 
overexpresses anti-apoptotic protein BCL-2,  MCF-7, a human breast adenocarcinoma cell 
line and HT-29, a human colon adenocarcinoma cell line.
Figure 5. Illustration of the two major apoptotic pathways (13).
Table  2. siRNAs,  targeted  at  different  cancer  biomarkers  or  cancer  relevant  genes  were  prepared  and  
transfected into carcinoma cell lines (MCF-7, 607B and HT-29) to evaluate the effect on cell viability and  
proliferation in order to identify possible synergistic effects.
gene name role up/down-regulation in cancer
aurora kinase A protein kinase, cell cycle control up
bcl-2 mitochondrial antiapoptotic protein up
calumenin calcium homeostasis, protein folding up
Cofilin-1 Actin-modulation, cytoskeleton up
regulation of cell growth and adhesion up
cyclin dependent kinase 1 protein kinase, cell cycle control up
EpCAM cell adhesion; migration, metastasis up
Galectin-1 Cell-cell interaction, proliferation up
GRP78 Protein-folding, hypoxia-induced up
GRP58 disulfide isomerase, protein folding up
Her2/neu protein kinase, signal transduction up
heat shock protein 60 protein folding, signal transduction up
heat shock protein 90 protein folding, signal transduction up
lactate dehydrogenase A anaerobic glycolysis up
myc cell cycle control, apoptosis regulation up
cell differentiation, metabolism up
protein kinase C protein kinase, signalling up
sphingosine kinase 1 proliferation, lipid signalling up
survivin apoptosis regulation up
VEGF angiogenesis, proliferation, apoptosis up
B-raf protein kinase, signal transduction up
Β-catenin
PPAR γ 
 2 Materials and Methods
 2.1  RNA synthesis and purification
Materials/Equipment
-Standard β-cyanoethylphosphoramidites for RNA and DNA synthesis [SAFC, Proligo 
Biochemie, Hamburg, Germany]
-Standard liquid reagents for DNA and RNA synthesis [SAFC, Proligo Biochemie, Hamburg, 
Germany]
-Diethyl-pyrocarbonate (DEPC) [Sigma-Aldrich, St. Louis, MO, USA] 
-10 column DNA-synthesizer [PolygenTM, Langen, Germany] 
Method
The RNA oligonucleotide sequences were synthesized on a DNA synthesizer according to 
the phosphoramidite method. This method consists of four repeating steps, detritylation (A), 
coupling (B), capping (C) and oxidation (D). The oligonucleotide is built up from the 3’-end 
to the 5’-end. Controlled Pore Glass (CPG) is used as solid phase. Standard RNA synthesis 
cycles  with  4.5-Dicyanoimidazol  (DCI)  as  activating  agent  were  used  for  all  syntheses. 
Successful coupling was monitored by measurements of trityl cations cleaved from the 5'-
hydroxy groups.
Purification
After synthesis 1.5 ml of ethanolic ammonium hydroxyde (EtOH/NH4OH 1:3) was added to 
the product and kept for 16 hours at room temperature to cleave the oligonucleotide from the 
solid phase. After removal of the solid phase, the supernatant was evaporated to dryness,  the 
residue redissolved in 10 µl anhydrous DMSO and heated for five minutes at 65°C for
 proper dissolution. Then 25 µl of triethylamine trihydrofluoride was added, the components 
were mixed briefly and heated to 65°C for 2.5 hours.
2  µl  3  M  sodium  acetate  (in  RNAse  free  water)  and  1  ml  butanol  were  added  and 
centrifugated for 10 minutes at 12000rpm. Butanol was decanted and the pellet was treated 
with 75% ethanol (750 µl), chilled for 10 minutes and centrifugated for 10 minutes at 12000 
rpm, repeated twice. 
To remove the ethanol traces the pellet was air-dried and redissolved in 50 µl of Rnase free 
water for storage at -20°C.
The  synthesized  oligonucleotides  were  diluted  1:10  and  OD260  was  determined  with 
NanoDrop.  The  extinction  coefficient  was  calculated  according  to  the  nearest-neighbor 
method  online  with  http://www.ambion.com/techlib/misc/oligo_calculator.html  and 
concentration was calculated via Lambert-Beer law. siRNA samples were diluted to a 10 µM 
stock solution. The purity was controlled by gel electrophoresis.
 2.2  Gel electrophoresis
RNA strands  were  analyzed  on denaturing  20% polyacrylamide  gels  (7.5  ml  Acrylamid 
stock-40%, 29:1 Acrylamid:bis-Acrylamid; 1.5 ml 10x TBE; 7.0 g Urea). Nucleic acids were 
mixed with formamide sample buffer (90% formamide, 2% 0.5 M EDTA, 8% water) for 
denaturation  (3  min  at  95°C,  immediately  cooled  on  ice).  Colored  sample  buffer 
(bromophenol blue) was used on two lanes. After a pre-run for 20 minutes at 150V with 
TBE buffer (89 mM Tris, 89 mM boric acid, 4% 0.5 mM EDTA), samples (1 nMol) were run 
on gels at the same constant voltage until bromophenol blue has reached about 2/3 of the gel 
length.
The gels were stained with methylene – blue (0.02% in TBE) for 30 minutes. 
 2.3  Cell culture
Materials/Equipment
-Dulbecco’s Modified Eagle Medium [GibcoTM, Invitrogen, Carlsbad, CA, USA] 
-Penicillin/Streptomycin [GibcoTM, Invitrogen, Carlsbad, CA, USA] 
-Fetal bovine serum, heat inactivated [GibcoTM, Invitrogen, Carlsbad, CA, USA] 
-HEPES [GibcoTM, Invitrogen, Carlsbad, CA, USA]
-LipofectamineTM 2000 [Invitrogen, Carlsbad, CA, USA]
-OptiMem® [GibcoTM, Invitrogen, Carlsbad, CA, USA]
-Trypsin/EDTA [GibcoTM, Invitrogen, Carlsbad, CA, USA]
-24-well plates [Iwaki, Tokyo, Japan]
-96-well plates [Greiner Bio-One, Kremsmünster, Austria]
-Cell culture flasks [Greiner Bio-One, Kremsmünster, Austria]
-Fluorescence microscope, Nikon Eclipse 50i [Nikon Instruments Inc., Europe]
-Microplate reader
-Thoma® cell counting chamber [Hawksley, Lancing, UK]
The human carcinoma cell lines 607B, MCF-7 and HT-29 were obtained from the European 
Collection of Cell Cultures (ECACC) and cultured in Dulbecco’s Modified Eagle Medium 
[GibcoTM, Invitrogen, Carlsbad, CA, USA] supplemented with 10% (v/v) fetal calf serum, 
100 U/ml penicillin, 100 μg/ml streptomycin, 6 mM L-glutamine. 
Figure  6.  MCF-7  carcinoma  cell  line  (picture  taken  from  
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?
ATCCNum=HTB-22&Template=cellBiology)
Figure  7.  HT-29  carcinoma  cell  line  (picture  taken  from 
http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/Default.aspx?
ATCCNum=HTB-38&Template=cellBiology)
 2.4  siRNA transfection
For  oligonucleotide  transfections  cells  were  grown  on  96-well  plates  (10000  cells/well, 
uncoated  plates)  until  cells  had  reached  70%  confluence  (24  hours  after  seeding). 
Oligonucleotides were pre-complexed with Lipofectamin2000TM in serum-free OptiMem® 
and transfected to 607B cells  24 hours after  seeding.  Three hours after  transfection with 
oligonucleotide-lipid complexes, serum was added to the cells to reach the normal growth 
media serum concentration.
siRNA oligonucleotides (10 µm stock solutions) were transfected at concentrations of 100 
nM,  10  nM  and  1  nM  for  single  agents  using  Lipofectamin  2000  (Invitrogen,  Life 
Technologies,Carlsbad, CA, USA) according to the manufacturer`s instructions.
In each transfection approach three different siRNAs were used in triplicates.
Effects of Lipofectamine
The  transfection  reagent  Lipofectamin  2000,  as  used  in  this  approach,  is  described  as 
cytotoxic in higher concentrations. The siRNA mediated gene knockdown on the other hand, 
only requires low nanomolar concentrations at which Lipofectamin did not show increased 
toxicity when transfected into the cell lines alone.
 2.5 RNA extraction and Bradford assay
RNA extraction
Cells  were  seeded in  24 wells  at  a  density  of  100000 cells  per  well  and transfected  in  
duplicates at a concentration of 100 nM and 10 nM for single siRNA agents. PeqGOLD 
TriFast Kit (Peqlab protocol, guanidinisothiocyanat/Phenol-method for RNA extraction) was 
used to isolate total RNA according to the manufacturer`s instructions.
Additionally required reagents were chloroform, isopropyl alcohol and ethanol.
In short the procedure required following steps: Homogenization (A), phase separation (B), 
RNA prezipitation (C) and washing (D). 
For homogenisization (A) 1.0 ml peqGOLD TriFast per well was added and incubated for 
five  minutes  at  room  temerature  to  allow  dissoziation  of  the  nucleotide-complexes. 
Centrifugation with 0.2 ml chloroform per sample for 5 minutes at  12000 rpm caused a 
formation of three phases (B) whereas RNA was dissolved in the aqueous phase exclusively.
For RNA precipitation (C) the aqueous phase was treated with 0.5 ml isopropyl alcohol, 
incubated for 15 minutes on ice and centrifugated for 10 minutes at 12000 rpm at 4°C. 
Subsequently  the  RNA precipitate  was  washed  (D)  twice  with  1  ml  ethanol  (75%)  by 
centrifugating (10 minutes, 12000 rpm, 4°C).
Afterwards the RNA pellets were redissolved in 20 µl of RNAse-freee water and stored at 
-20°C for further use.
For cDNA synthesis - calculations, RNA extracts were measured with NanoDrop. (analog 
procedure for BCL-2, Her2/Neu and EpCAM). For cDNA-sythesis, depending on different 
concentrations, 500 ng or 50 ng of siRNAs were used.
Bradford 96 – well assay
For  evaluation  of  purity  of  the  RNA –  extracts,  the  overall  protein  concentration  was 
calculated using the Bradford assay.
I  worked with  a  calibration  curve using 0,  2,  4,  6,  8,  10,  15,  20 µl  BSA (1 mg/ml)  in  
duplicates (ad 20 µl H²O) plus 180µl Bradford reagent. 
The samples persisted of 5, 10, 15 µl (ad 20 µl H²O) plus 180 µl Bradford reagent.
Absobance was measured at 595 nm with Infinite 200 PRO microplate reader (Tecan Group 
Ltd., Männedorf, Switzerland), protein concentrations were calculated using the calibration 
curve.
No significant protein – concentrations were detectable in the RNA extraction.
Figure 8. BSA - calculated standard curve
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 2.6  Native agarose gel  electrophoresis for  RNA evaluation and  
PCR products
This gel electrophoresis was performed to evaluate the overall quality of the extracted RNA 
by inspection of the 28S and 18S rRNA bands. 
A 1.5 % agarose gel (3 g agarose, 200 ml of 1x TAE, 10 µl ethidium bromide) was loaded 
with RNA (2 µl) mixed with 2 µl 2X RNA Loading Dye (Fermentas).
Samples were run on gels at 150 V for 90 minutes in 1x TAE (diluted from a stock of 50x 
TAE buffer-242 g Tris base, 57.1 ml Acetic acid, 100 ml 0.5 M EDTA, adjusted to ph 8.0).
The gels were vizualized with Quantity One® 1D analysis software, version 4.6 [Bio-Rad 
Laboratories, München, Germany] . 
The same agarose gel was prepared to assess the quality of PCR products and the primers. 
Sample (1 µl) was mixed with 5 µl of 6X DNA Loading Dye (Fermentas). After a pre-run in 
1x TAE at 150 V for 30 minutes, the samples were run for 90 minutes at the same constant  
voltage.
 2.7  Proliferation- and Apoptosis assay
Proliferation assay
Cells were seeded in 96 wells at a density of 10000 cells per well and transfected with three 
different siRNAs. After 48 hour of incubation at 37°C, the cell viability/proliferation was 
assayed  using  the  EZ4U-kit,  a  nonradioactive  cell  proliferation  and  cytotoxity  assay 
(Biomedica Gruppe), according to the manufacturer`s instructions.
The technique is based on the reduction of colourless tetrazolium salts to intensely coloured 
formazan derivates in mitochondria of living cells.
This reduction requires faultless mitochondria. Due to the fact that mitochondria are inactive 
within minutes after cell death, this method provides an excellent possibility to discriminate 
between living and dead cells.
The quantity of Formazan was determined with Infinite 200 PRO microplate reader (Tecan 
Group Ltd., Männedorf, Switzerland) after  30, 150 and 210 minutes  of incubation time at 
37°C by measuring absorbance at 450 nm to determine changes in extinction.
The results were presented with data after 210 minutes.
The absorbance value from a blank-triplicate without cells  was subtracted from all  other 
values. siRNA treated samples were referenced to untreated cells.
Figure 9.  Reduction of Tetrazolium
Apoptosis assay
This assay is based on the hydrolysis of the peptide substrate acetyl-Asp-Glu-Val-Asp-7-
amido-4-methylcoumarin  (As-DEVD-AMC) by caspase 3,  resulting in  the release  of  the 
fluorescent  7-amino-4-methylcoumarin  (AMC)  moiety  [Sigma  Caspase  3  Assay  Kit, 
Technical Bulletin]
Cells were seeded in 96 wells  (fluorimeter multiwell plate)  at a density of 10000 cells per 
well  and transfected  with three different siRNAs (see fig. transfection scheme).  After  48 
hour of incubation at 37°C a caspase 3 fluorimetric assay (Sigma-Aldrich, Missouri, USA) 
was performed.
96 well plate was placed on ice. 25 µl of 1x lysis buffer (5x lysis buffer: 250 mM HEPES, ph 
7.4, 25 mM CHAPS and 25 mM DTT) was added per well and incubated on ice for 20  
minutes. Then 200 µl of 1x assay buffer (10x assay buffer: 200 nM HEPES, ph 7.4, 1% 
CHAPS, 50 mM DTT and 20 mM EDTA) containing As-DEVD-AMC-substrate (5 µl of 10 
mM As-DEVD-AMC to 3 ml of 1x assay buffer) was added per well (plus three wells of 
substrate blanks). 
AMC product was measured at 360 nm (excitation) and 460 nm (emmision) with Infinite 200 
PRO microplate reader (Tecan Group Ltd., Männedorf, Switzerland) in six kinetic circles 
every 10 minutes. 
 2.8  Reverse Transcription
Starting from total RNA after RNA Cleanup, cDNA was obtained by reverse transcription 
(RevertAid® Reverse Transcriptase Kit,  Fermentas Life Sciences).  First,  1 μl  of random 
hexamer primers (0.2 µg/µl) was added to each sample and to 12.5 µl with DEPC-treated 
water. In order to eliminate secondary structures, especially if RNA – templates are GC rich, 
samples were incubated at 65°C for five minutes, then briefly centrifugated and placed on 
ice.  Then  master  mix  was  added  per  sample  (total  volume of  20  µl),  consisting  of  the 
following components:
4 μl 5X Reaction Buffer (250 mM Tris-HCl (ph 8.3), 250 mM Kcl, 20 mM MgCl², 50 mM 
DTT)
2 μl dNTP Mix, 10 mM each
2 μl Ribolock® RNase inhibitor 
1 µl of RevertAid® Reverse Transcriptase 
The  sample  was  incubated  at  room  temperature  for  10  minutes  and  then  placed  in  a 
thermoblock at  42°C for 60 minutes.  Finally,  the sample was incubated at  70 °C for 10 
minutes to terminate the reaction. cDNA samples were stored at -20 °C.
 2.9  PCR and realtime PCR
PCR
For PCR the peqlab PCR Kit was used.
To minimize the possibility of pipetting errors, a mastermix was prepared, consisting of the 
following components:
5 µl 10x Reaction Buffer (100 nM Tris-HCl [ph 8.8], 500 nM Kcl, 0.1% Tween 20, 15 mM 
MgCl²)
1 µl dNTP Mix (40 mM)
1 µl upstream Primer
1 µl downstream Primer
0.5 µl Taq – DNA – Polymerase (5 u/µl)
ad 50 µl ddH²O
Then 5 µl of template DNA was added and PCR was performed using following thermal 
cycling conditions:
Table 3. cycling conditions
Step T (°C) Time Number of cycles
Initial denaturation 95 3 min 1
Denaturation 95 30 s
Annealing Tm-5 30 s 25-40
Extension 72 1min/kb
Final extension 72 15 min 1
Realtime PCR
Real-time  PCR  was  performed  using  KAPA  SYBR® FAST  qPCR  Kit  (Peqlab 
Biotechnologie GmbH, Erlangen, Germany) in 20 µl reactions. For each biological sample 
two separate reactions were set up.
Reaction setup:
10 µl KAPA SYBR® FAST qPCR MasterMix (2x) Roche LightCycler® 480
0.4 µl forward Primer
0.4 µl reverse Primer
4.2 µl PCR grade water
5 µl template DNA
The cycling protocol was performed according to the manufacturer`s instructions. Cp values 
were determined with the Light  Cycler  software.  Relative quantification was done using 
Excel.
 3 Results
At the beginnings of my work several siRNAs targeted at different cancer biomarkers had 
been characterized and were chosen as potential sequences for a multi-target approach for 
cancer therapy. Some were identified from studies with BCL-2-targeted oblimersen which 
increased the number of influenced proteins and the extend of downregulation, suggesting a 
synergystic effect of BCL-2 downregulation in 607B melanoma cells (34).
The genes of interest all play an important role in cancer metabolism. In being upregulated in 
different  tumor  cell  lines,  they  may  be  causational  in  the  development  and  progress  of 
cancer.
A knockdown of these target genes was performed by transfecting carcinoma cell lines with 
respective siRNA sequences. siRNAs, in different combinations,  were examined for their 
ability  to  cause a synergistic  effect  on cell  viability  and proliferation of carcinoma cells 
compared to targeting only one of these genes.
A panel of human carcinoma cell lines, consisting of 607B, HT-29 and MCF 7, were chosen 
for these experiments.
The  random target  combinations  in  the  proliferation  assays  indicated  six  siRNAs which 
seemed to have strong effects in downregulating target genes of the tested carcinoma cell 
lines. They are described as follows:
 3.1 Her2/Neu
The  role  of  HER/neu  proto-oncogene,  overexpressed  in  breast  cancer  cells,  has  been 
investigated in different studies. The HER2/neu (c-erbB-2) proto-oncogene encodes a trans- 
membrane  protein  tyrosine  kinase  growth  factor  receptor,  p185HER2,  a  member  of  the 
human epidermal growth factor receptor family. About 30% of human breast cancers and 
several  other  cancer  types overexpress Her2/neu.  HER2/neu overexpression is  associated 
with a poor clinical outcome, including a positive correlation with metastasis (14, 15).
The  method  of  using  antisense  oligonucleotides  (ASOs)  to  inhibit  gene  expression 
selectively (16) showed limited therapeutic effects due to toxicity and different side effects in 
all likelihood arising from inhibition through other mechanisms (17).
Antiproliferative effects of HER2/neu – specific ASOs has been evaluated in HER2/ neu – 
overexpressing breast cancer cells transfected with ASOs (concentration: 1 µM) (18) and , 
using synthetic siRNAs targeted on Her2/Neu, breast cancer cell line MCF-7 underwent gene 
silencing of HER2/neu after treatment with HER2/neu – specific siRNA (19).
Figure 10. Key targets for breast cancer treatment. (35)
 3.2 EpCAM
The name EpCAM (epithelial cell adhesion molecule) was first suggested by Litvinov et al. 
(20, 21). EpCAM is encoded by the GA733-2 gene located on the long arm of chromosome 
4.  It  is  a  Mr 40,000,  type  I  transmembrane glycoprotein  that  consists  of  two epidermal 
growth factor-like extracellular domains, a cysteine-poor region, a transmembrane domain, 
and a short cytoplasmic tail (22). 
Several studies identified EpCAM to be overexpressed by the majority of human epithelial 
carcinomas including colorectal and breast carcinomas (23, 24) and the use of the EpCAM- 
specific monoclonal antibody has been successful in increasing disease-free survival in colon 
and breast cancer patients with minimal residual disease (25, 26) 
EpCAM signalling pathways:
Figure 11. Schematic of signaling pathways of EpCAM (36)
 3.3 Galectin-1
Galectin-1, a member of the galectin family, is a dimer lectin, which expression has been 
well documented in different types of tumors including colon carcinomas. Due to the fact 
that tumour metastasis is a multistep process including changes in cell adhesion, increased 
invasiveness, angiogenesis and evasion of the immune response and intracellular galectin-1 
has been shown to contribute to all these processes, it presumably plays a key role in tumor 
growth (27).
As showed in Figure 7, galectin-1 modulates cell growth, cell adhesion and cell migration 
which affects the process of tumour metastasis.
Figure 12. Contribution of galectin-1 to tumour progression (27).
 3.4 ß-catenin 
In normal epithelial cells, ß-catenin is found at the plasma membrane where it provides a 
mechanical  linkage  between  cell-to-cell  junctional  proteins  (e.g.,  E-cadherin)  and 
cytoskeletal proteins (e.g., ß-catenin and actinin-4) (28, 29). By contrast, in tumor cells, ß-
catenin is often found in the cytoplasma and nucleus where it associates with TCF family 
members to form a complex, which activates transcription of pro-mitotic proteins including 
c-Myc and cyclinD1.
Figure  13. Signal  transduction  pathways  modulating  ß-catenin  
localisation  and  degradation.  (Figure  and  legend  taken  from 
http://www.valasciences.com/articles/applications/monitoring-expression-
and-distribution-of-catenin-z-05/)
 3.5 BCL-2
BCL-2 itself was the first intracellular regulator of apoptosis to be identified (30). Since the 
role of apoptosis in cancer development became more understood, BCL-2 appears to be a 
promising target in cancer research.
The  BCL-2  protein  family  is  regulated  by  transcriptional  and  post-transcriptional 
mechanisms. Irreparable cellular stress, such as DNA damage, leads to accumulation of pro-
apoptotic signaling and results in mitochondrial outer membrane permeabilization (MOMP). 
This  leads  to  the  “apoptosome”  complex.  Pro-caspase-9  is  recruited  and  activates 
executioner  caspases  (  caspase-3,  -6  and  -7)  that  cause  the  characteristic  phenotypes  of 
apoptosis by cleaving different intracellular substrates (37).
FIGURE 14. The mitochondrial pathway of apoptosis (37)
 3.6  siRNA control
After preparing the RNA sequences on the Polygen Synthesizer, the products were cleaved 
from the solid support and deprotected. The 2’-silyl group was removed with 
triethylammonium-trihydrofluoride and the purity of the deprotected oligonucleotides was 
checked on a denaturing polyacrylamide gel. Generally, all products had good purity with 
only slight appearance of failure sequences and were used for cell culture studies without 
further purification.
Figure 15. siRNA products
 3.7 RNA evaluation
The RNA integrity was verified on an agarose gel via 28S and 18S bands of the total RNA 
extractions. 28S band should be approximately twice as intense as the 18S band, indicating 
intact RNA. Partially degraded RNA would appear as a lower molecular weight smear, 
lacking the sharp rRNA bands.
Figure 16. rRNA bands
 3.8  PCR Primercontrol
For evaluation of adequate primers for qPCR and their proper amplicon length, a primer 
control was performed via gelelectrophoresis. 
Figure 17. Primercontrol with Bcl-2
 3.9  qPCR
The depletion of the targeted mRNA by siRNA gene silencing was verified with qPCR 
analyses.
The  cells  were  seeded  on  24  wells  at  a  density  of  100000  per  well  and  transfected  in 
duplicates with single siRNAs agents (concentrations: 100 nM and 10 nM) and combinations 
of three siRNAs (concentrations: 300 nM and 30 nM). 607B were transfected with siRNAs 
specific for ß-catenin, sphingosine kinase 1 and galectin-1, MCF-7 with Her2/Neu, EpCAM 
and BCL-2. Overall RNA was extracted and cDNA was synthesized.
After designing suitable primers and testing for specific amplification, mRNA levels were 
quantified by qPCR using Sybr Green and actin for normalization. Despite testing several 
primer pair, no specific primer systems were found for Her2/neu and ß-catenin.
For the calculation of the different levels of expression I chose the  ∆∆CP method:
∆CP = CP target gene – CP reference gene
∆∆CP=∆CP treated – ∆CP control
Ratio= 2^(–∆∆CP) 
This method implies a doubling of DNA per cycle, an optimal efficiency of the real-time 
PCR (E=2). In order to evaluate true primer-efficiencies, I prepared a standard curve of each 
primer pair (dilutions 1:1, 1:4, 1:16 and 1:64). The used amount of cDNA was plotted against 
the CP in a logarithmic function and calculated with the formula:
E=10^(-1/k)
Consequently  efficiencies  for  each  gene  were  calculated  and used  for  calculation  of  the 
expression ratio.
Figure 18. The primer efficiency of BCL-2
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Table 4. real efficiencies
gene efficiency
actine 2.24
Bcl-2 1.82
Her2/Neu 1.763
EpCAM 1.8407
galectin-1 1.8614
sphingosine kinase 1 1.711
Verification of successful target down regulation using qPCR
a)
b)
Figure 19. Expression ratios (light grey: 100 nM; grey: 10 nM, respectively 30 nM at the combination) of a)  
BCL-2 and b) EpCAM compared to untreated cells.
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All assayed mRNAs showed high extent of reduction after treatment with the respective 
specific siRNA even at concentrations of 10 nM. EpCAM mRNA was reduced to under 20 
% of the untreated samples, bcl-2, galectin-1 and sphingosine kinase 1 to less than 10 % of 
the original value. With the exception of galectin-1, an increase of siRNA concentration to 
100 nM did not cause a higher extent of downregulation, indicating saturation at already 10 
nM. The fact that bcl-2 mRNA levels are higher after treatment with 100 nM siRNA may be 
explained by incomplete transfection and cell death of transfected cells. Consequently 
untransfected cells are overrepresented in the analysis sample.
When applied together with two other siRNA double strands, the target downregulation was 
generally not impaired. Due to rather high toxicity of high lipofectamine amounts, RNA 
yields of samples treated with combinations of 100 nM of each siRNA (300 nM total) were 
too low for qPCR analysis. With the exception of the bcl-2 values, all mRNA levels were 
reduced to roughly the same level after applying 30 nM of mixed siRNAs (10 nM of each 
sequence) or the mono-treatment with gene-specific siRNA. These results prove that by 
mixing different siRNA agents, the specific effect is not abolished.
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Figure  20.  Expression  ratios  (light  grey:  100  nM;  grey:  10  nM,  respectively  300 nM and 30  nM at  the 
combinations) of a) galectin-1 and b) sphingosin kinase 1 compared to untreated cells. 
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 3.10 Proliferation assay
For evaluation of the effect on cell proliferation a formazan dye-based proliferation assay 
was performed. siRNAs were transfected as single agents and in various combinations of two 
to three sequences into the carcinoma cell lines MCF-7, HT-29 and 607B, preferably using 
multiple siRNA targets from different intrinsic pathways per approach.  To exclude effects 
caused by dose-dependent toxicity of the transfection reagent, a non-specific sequence 
(scrambled lactate dehydrogenase A) was used as a control and all values were normalized to 
the controls. All transfections were performed in triplicates. 
siRNAs targeted at the following genes seemed  to  decrease  the  cell  proliferation  most 
efficiently and were therefore encircled for further investigations: Her2/Neu, EpCAM, BCL-
2, ß-catenin, sphingosine kinase 1 and galectin-1.
HT-29 was additionally treated with siRNAs specific for survivin, VEGF and EpCAM.
a)
survivin
VEGF
EpCAM
contr.1x
sur/VEGF
sur/EpCAM
VEGF/EpCAM
sur/VEGF/EpCAM
contr. 3X
0
50
100
150
HT-29
%
 o
f u
nt
re
at
ed
b)
Her2
EpCAM
Bcl-2
contr. 1x
Her2/EpCAM
Her2/Bcl-2
EpCAM/Bcl-2
Her2/EpCAM/Bcl-2
contr. 3x
0
50
100
150
607B
%
 o
f u
nt
re
at
ed
c)
Figure  21.  Proliferation  assays  measured  48  hours  after  transfection  (incubation  time  after  sample  
preparation: 210 minutes in each proliferation assay). Cells were transfected at concentrations of 100 nM  
(black), 10 nM (grey) and 1 nM (white), respectively double and triple concentrations in the combinations;  
control 1x: lactate dehydrogenase A/ctrl at 100, 10 and 1 nM; control 3x: lactate dehydrogenase A/ctrl at  
300, 30 and 3 nM;
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Figure  22.  Proliferation  assays  measured  48  hours  after  transfection  (incubation  time  after  sample  
preparation: 210 minutes in each proliferation assay). Cells were transfected at concentrations of 100 nM  
(black), 10 nM (grey) and 1 nM (white), respectively double and triple concentrations in the combinations;  
control 1x: lactate dehydrogenase A/ctrl at 100, 10 and 1 nM; control 3x: lactate dehydrogenase A/ctrl at  
300, 30 and 3 nM;
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From the proliferation data, differences in the effects of siRNA-mediated downregulation 
depending on the cell line are apparent. Transfections of single siRNAs generally had no 
significant effects on the proliferation rates, with the exception of sphingosine kinase 1 
(607B), galectin-1 (HT-29), and β-catenin (607B and HT-29). A number of arbitrary 
combinations were evaluated for their effect on proliferation. No siRNA combination 
showed synergistic effect on all evaluated cell lines. In MCF-7, several mixtures of two 
siRNAs resulted in an increased effect over their single components. siRNA directed at 
Her2/EpCAM, Her2/bcl-2, and EpCAM/bcl-2 all resulted in significant decrease of cell 
growth. The same combinations did not give similar results in the melanoma cell line 607B.
Her2/Neu  and  EpCAM  are  strong  breast  cancer  cell-markers,  but show only limited 
expression in melanoma.
siRNA treatment against ß-catenin, sphingosine kinase 1 and galectin-1 was performed in all 
three cell lines. HT-29 and 607B, despite reducing proliferation rates after mono-transfection 
of some of the siRNAs (see above), lower or equal reductions of proliferation resulted when 
combining those siRNA sequences. In particular, in HT-29 the effect of the ß-catenin-siRNA 
was abolished by combining it with either galectin-1- or sphingosine kinase 1-specific 
siRNA. In the melanoma cell line, the proliferation reduction remained the same, indicating 
no potential synergy of these combinations. In MCF-7, significant reductions of proliferation 
were detected with these siRNA combinations. However, these results are compromised by a 
high variation within this particular assay and the lack of concentration dependence of some 
samples; Sk-1/gal-1 and sk-1/ß-cat demonstrated higher toxicity at 10 and 1 nM than at 100 
nM – concentration. 
Effects on HUVECs
In order to find target combinations with selectivity on cancer cells, HUVEC cells were used 
as controls.
a)
b)
Figure 23. a,b) Human umbilical vein endothelial cells (HUVECs), treated with same target combinations,  
as a control for somatic endothelial tissue. 
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 3.11 Caspase assay
To  measure  apoptosis  induction,  and  distinguish  from  unspecific  necrosis  and  toxicity 
effects, a caspase activity assay based on the cleavage of the DEVD-peptide was performed 
with  the  previously  identified  siRNA sequences  Her2/Neu,  EpCAM,  BCL-2,  ß-catenin, 
sphingosine kinase 1 and galectin-1.
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Confirming the results  of the proliferation test,  both,  ß-catenin,  sphingosin kinase 1 and 
galectin-1 in  combination and ß-catenin  as  a  single  agent,  led to  an  increase  in  caspase 
activity in 607B. ß-catenin had an even higher effect on apoptosis of the human melanoma 
cell line, followed by EpCAM and sphingosine kinase 1. 
ß-catenin, sphingosine kinase 1 and galectin-1 siRNAs transfected into MCF-7 also led to 
increased caspase activity.
Whereas the Her2/EpCAM/BCL-2 – combination in MCF-7 did indicate a significant effect 
on proliferation compared to the control, in this approach, with the same combination, no 
increase in caspase activity is visible. 
Figure 24. a,b) Caspase activities of the indicated siRNAs measured 48 hours after transfection.
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 4 Discussion
The knowledge from earlier studies both on off-target effects and on different gene-silencing 
projects via RNA interference mechanism showed a potential  in downregulating multiple 
cancer relevant genes by targeting only one of these genes.
While genome-wide siRNA screens, comprising around 18 000 different genes, are available 
today, mathematical and practical aspects prevent large scale screening of synthetic lethality, 
i.e. cell death caused by depletion of two or more genes, but not by downregulation of one of 
those genes alone. Even when applying only 100 genes with known involvement in cancer 
progression, there are already 4950 possible dual combinations and 161700  possible triple 
combinations. Consequently, for elucidation of novel synergistically lethal siRNA 
combinations, it is necessary to use a rational, small-scale approach.
Thus, I focused on a relatively small number of siRNA targets that play a significant role in 
known  cancer  relevant  pathways  such  as  apoptosis  regulation,  cell  cycle  control, 
angiogenesis or proliferation. 
The aim was to  combine siRNAs which cover  different  metabolic  pathways in  order  to 
achieve reduced proliferation rates and increased apoptosis rate of the treated cells. In order 
to prevent false positive and false negative results, the extent of target downregulation was 
quantified by qPCR.
So this diploma thesis was devoted to the question whether different combinations of cancer 
relevant siRNA targets induce increased toxicity in carcinoma cell lines (607B, MCF-7, HT-
29) in order to find possible synergistic effects in the extent of downregulating these targets. 
Using initial results from a formazan dye-based proliferation assay, six siRNA targets were 
chosen  for  recombination  transfection  experiments:  Her2/Neu,  BCL-2,  EpCAM  and 
galectin-1, ß-catenin, sphingosine kinase 1. 
Unlike for screening experiments,  successful dose-dependent mRNA downregulation was 
verified by establishing qPCR assays for the respective genes. With the exception of Her2, 
suitable primer combinations were found for all genes. For bcl-2 and EpCAM, the extent of 
downregulation was found to be slightly decreased after transfection of a mixture of different 
siRNAs. This could be due to hybridization-dependent interactions of the RNA strands (six 
in total), resulting in duplex binding other than the intended ones. Another explanation could 
be  a  lower  transfection  efficiency.  In  contrast,  the  extent  of  mRNA reduction  was  not 
affected by transfection of mixtures for Sk-1 and galectin-1. 
The used delivery system for siRNAs was lipofectamine, a stable nucleic acid lipid particle 
(SNALP) which is described as cytotoxic in higher concentrations. In order to avoid false-
positive data in the range of cell  proliferation and apoptosis,  cells  were transfected with 
lipofectamine as a control. At higher concentrations (100 nM) the cells showed significant 
decrease in proliferation which, in all likelihood, can be attributed to its toxicity. Due to the 
inherent toxicity of lipofectamine, triple combinations applied in higher concentrations also 
lead to significant loss of cells and consequently low RNA yields. Therefore, no reliable 
mRNA quantification was possible for samples treated with 100 nM concentrations of each 
siRNA.
The results from this pilot study for the identification of siRNA target combinations reveal a 
high  dependence  on  the  tumor  cell  line.  To  examine  possible  effects  on  healthy  tissue, 
HUVECs were transfected with the same siRNA combinations. Caused by low proliferation 
rates, variation between the samples were high, and no reliable target- and dose-dependent 
effects resulted. Optimization of the transfection and readout procedure is necessary to adopt 
the experiment for primary HUVECs.
The  most  significant  result  in  the  proliferation  assays  was  a  synergistic  effect  of  the 
downregulation of the mammary cancer-markers Her2/Neu and EpCam, both together and 
with the antiapoptotic bcl-2, in the breast cancer cell line MCF-7. The same was not the case 
for the melanoma cell line 607 B, which shows only very limited expression of EpCAM and 
Her2.  This  and other  results  highlight  the  heterogeneity  of  tumors  and demonstrate  that 
specific siRNA treatment is very likely dependent on the particular tumor phenotype. 
A number of the chosen siRNAs influenced apoptosis and proliferation both as single agents 
and in combinations in 607B, MCF-7 and HT-29 but for an establishment as therapeutics still 
many difficulties like effective drug delivery and cellular uptake,  toxicity of the delivery 
system, or the question of specificity arise.
As  targeting  cancer  relevant  genes  with  suitable  siRNA appeared  to  have  an  important 
impact  to  cell  proliferation,  viability and apoptosis  in different  melanoma/carcinoma cell 
lines,  it  is  predicted  that  further  studies  of  possible  synergistic  combinations  will  be 
performed and might lead to cancer clinical trials. 
Additionally a challenge for future in-vivo studies will be to find non-toxic siRNA-delivery 
systems for the cell.  So for the  development  as therapeutics,  the question of the inward 
transfer of siRNAs still remains a major safety problem.
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